Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders

Experimental Neurology

Volumn 225, Issue 2, 2010, Pages 384-390

  Hodgson, Robert A ^a   Bedard, Paul J ^b   Varty, Geoffrey B ^a   Kazdoba, Tatiana M ^a   Di Paolo, Therese ^b   Grzelak, Michael E ^a   Pond, Annamarie J ^a   HadjTahar, Abdallah ^b   Belanger, Nancy ^b   Gregoire, Laurent ^b   Dare, Aurelie ^a   Neustadt, Bernard R ^a   Stamford, Andrew W ^a   Hunter, John C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

A2A; Adenosine; Extrapyramidal Syndrome; Monkey; Movement disorder; MPTP; Parkinson's Disease; Preladenant

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; HALOPERIDOL; LEVODOPA; PRELADENANT; UNCLASSIFIED DRUG; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE A2 RECEPTOR ANTAGONIST; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CEBIDAE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DYSKINESIA; EVOKED RESPONSE; EXTRAPYRAMIDAL SYNDROME; FEMALE; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; OPTIMAL DRUG DOSE; PARKINSON DISEASE; PRIORITY JOURNAL; ANALYSIS OF VARIANCE; ANIMAL; BASAL GANGLIA DISEASES; BASAL GANGLION; CEBUS; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; MACACA FASCICULARIS; METABOLISM; MOTOR ACTIVITY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; AREA UNDER CURVE; BASAL GANGLIA; BASAL GANGLIA DISEASES; CEBUS; DISEASE MODELS, ANIMAL; FEMALE; MACACA FASCICULARIS; MALE; MOTOR ACTIVITY; PYRIMIDINES; RECEPTOR, ADENOSINE A2A; TRIAZOLES; ADENOSINE A2 RECEPTOR ANTAGONISTS;

EID: 77956424883     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.07.011     Document Type: Article

References (42)

1. Arai N., Isaji M., Miyata H., Fukuyama J., Mizuta E., Kuno S. Differential effects of three dopamine receptor agonists in MPTP-treated monkeys. J. Neural Transm. Park Dis. Demen. Sect. 1995, 10:55-62.
2. Arai N., Isaji M., Kojima M., Mizuta E., Kuno S. Combined effects of cabergoline and l-Dopa on parkinsonism in MPTP-treated cynomolgus monkeys. J. Neural Transm. 1996, 103:1307-1316.
3. Bedard P.J., Di Paolo T., Falardeau P., Boucher R. Chronic treatment with l-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res. 1986, 379:294-299.
4. Bibbiani F., Oh J.D., Kielaite A., Collins M.A., Smith C., Chase T.N. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp. Neurol. 2003, 184:285-294.
5. 2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 2004, 127:1075-1084.
6. Casey D.E. Extrapyramidal syndromes in nonhuman primates: typical and atypical neuroleptics. Psychopharmacol. Bull. 1991, 27:47-50.
7. Casey D.E. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol. 1995, 10:105-114.
8. Casey D.E., Keepers G.A. Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. Psychopharmacol. Ser. 1988, 5:74-93.
9. Chen J.F., Xu K., Petzer J.P., Staal R., Xu Y.H., Beilstein M., Sonsalla P.K., Castagnoli K., Castagnoli N., Schwarzschild M.A. Neuroprotection by caffeine and A(2A) adenosine inactivation in a model or Parkinson's disease. J. Neurosci. 2001, 15:RC143.
10. 1 receptors. J. Pharmacol. Exp. Ther. 1989, 249:769-774.
11. 2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav. Brain Res. 2004, 148:47-54.
12. 2A receptor knockout mice are partially protected against drug-induced catalepsy. Neuroreport 2001, 17:983-986.
13. 2 agonists and antagonists on dyskinesia produced by l-DOPA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyriding-treated monkeys. J. Pharmacol. Exp. Ther. 1991, 251:409-413.
14. 2A receptor antagonist in MPTP-treated monkeys. Neurology 1999, 52:1673-1677.
15. 2A receptor antagonist istradefylline in advanced PD. Neurology 2003, 61:297-303. the Istradefylline US-001 Study Group.
16. Hauser, R.A., Pourcher, E., Micheli, F., Mok, V., Onofrj, M., Huyck, S., Wolski, K., Cantillon, M. Efficacy of Preladenant, a Novel A2A Antagonist, as an Adjunct to Levodopa for the Treatment of Parkinson's Disease. Movement Disorder Society Meeting 2009: Tu-185.
17. Henry B., Crossman A.R., Brotchie J.M. Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of l-dopa-induced dyskinesia. Adv. Neurol. 1998, 78:53-61.
18. 2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J. Comp. Neurol. 2001, 431:331-346.
19. 2A receptor antagonists SCH 412348 and preladenant in rodent models of movement disorders and depression. J. Pharmacol. Exp. Ther. 2009, 330:294-303.
20. Huyck, S., Wolski, K., Cantillon. Impact of A2A Receptor Antagonist Pr eladenant on Dyskinesia in Moderate to Severe Parkinson's Disease: Post Hoc Analysis of Dose-Finding Study. Movement Disorder Society Meeting 2009: Tu-187.
21. 2A receptor antagonist with anticataleptic activity. Eur. J. Pharmacol. 1994, 256:263-268.
22. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 1998, 43:507-513.
23. 2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol. 2000, 162:321-327.
24. Karcz-Kubicha M., Antoniou K., Terasmaa A., Quarta D., Solinas M., Justinova Z., Pezzola A., Reggio R., Müller C.E., Fuxe K., Goldberg S.R., Popoli P., Ferré S. Neuropsychopharmacology 2003, 28:1281-1291.
25. Koga K., Kurokawa M., Ochi M., Nakamura J., Kuwana Y. Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur. J. Pharmacol. 2000, 408:249-255.
26. 2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4, 3-e]-1, 2, 4-triazolo[1, 5-c]pyrimidines. Bioorg. Med. Chem. Lett. 2007, 17:1376-1380.
27. Ochi M., Koga K., Kurokawa M., Kase H., Nakamura J., Kuwana Y. Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience 2000, 100:53-62.
28. Ochi M., Shiozaki S., Kase H. Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease. Neuroscience 2004, 127:223-231.
29. 2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci. Lett. 1996, 212:53-56.
30. Pearce R.K., Banerji T., Jenner P., Marsden C.D. De novo administration of ropinirole and bromocriptine induces less dyskinesia than l-Dopa in the MPTP-treated marmoset. Mov. Disord. 1998, 13:234-241.
31. 2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. Synapse 2007, 61:606-614.
32. 2A receptor antagonist ST1535 potentiates the effects of a threshold dose of l-DOPA in MPTP treated common marmosets. Eur. J. Pharmacol. 2006, 546:82-87.
33. 2A antagonists: implications for parkinsonism. Front. Biosci. 2008, 13:3594-3605.
34. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 1999, 147:90-95.
35. 2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp. Neurol. 2004, 189:182-188.
36. Tarsy D. Tardive dyskinesia. Curr. Treat. Options Neurol. 2000, 2:205-214.
37. Trevitt J.T., Lyons M., Aberman J., Carriero D., Finn M., Salamone J.D. Effects of clozapine, thioridazine, risperidone and haloperidol on behavioral tests related to extrapyramidal motor function. Psychopharmacology 1997, 132:74-81.
38. 2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur. J. Pharmacol. 2007, 566:94-102.
39. 2A receptor antagonists on haloperidol-induced movement disorders in primates. Psychopharmacology 2008, 200:393-401.
40. Wichmann T., DeLong M.R. Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder. Ann. N.Y. Acad. Sci. 2003, 991:199-213.
41. 2A receptors contribute to l-3, 4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J. Neurosci. 2006, 26:13548-13555.
42. Yamamoto N., Pierce R.C., Soghomonian J.J. Subchronic administration of l-DOPA to adult rats with a unilateral 6-hydroxydopamine lesion of dopamine neurons results in a sensitization of enhanced GABA release in the substantia nigra, pars reticulata. Brain Res. 2006, 1123:196-200.